ArticleFrontiers in pharmacology2025
Exploratory research on therapeutic agents combined with early diagnostic biomarkers for colorectal cancer.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib.Journal of clinical medicine · 2026Review
- Commentary: Exploratory research on therapeutic agents combined with early diagnostic biomarkers for colorectal cancer.Frontiers in pharmacology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide. Although diagnostic and therapeutic strategies have advanced, the molecular mechanisms driving CRC pathogenesis are not fully understood, highlighting the need for novel biomarkers and therapeutic agents. Methods: Integrated bioinformatics analyses of transcriptomic datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were performed to identify survival-associated differentially expressed genes (DEGs) in CRC (|log2FC| > 1.5, p < 0.05). These key DEGs were then used to query the L1000FWD, DGIdb, and CMap platforms to predict candidate small-molecule drugs. The top candidate was evaluated by molecular docking, and its anti-tumor effects were validated by MTT cell viability assays in CRC cell lines. Results: We identified 15 survival-associated DEGs-MELK, NFE2L3, MCM2, MAD2L1, AUNIP, CXCL3, GLDN, GREM2, ALDH1A1, CILP, FABP4, AOC3, CNN1, ANGPTL1, and DES-as potential early diagnostic biomarkers for CRC. Drug-repositioning analyses convergently highlighted SB-225002 as a promising therapeutic agent. Molecular docking showed high binding affinity of SB-225002 to multiple key targets. MTT assays demonstrated that SB-225002 exerted dose-dependent inhibitory effects on the proliferation of CRC cell lines (SW-480, DLD-1, and MC38), with IC50 values of 2.307 μM, 0.9456 μM, and 3.449 μM, respectively. Discussion: This study systematically delineates a novel panel of early-detection biomarkers for CRC and identifies SB-225002 as a repurposed candidate therapeutic agent. The integrative strategy combining multi-cohort transcriptomic analysis, drug-repositioning platforms, molecular docking, and experimental validation offers a feasible framework for discovering clinically actionable biomarkers and small-molecule therapies for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.